JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB318947

Recombinant Human NRAS (mutated G12D) Protein (His tag)

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant Human NRAS (mutated G12D) Protein (His tag) is a Human Full Length protein, expressed in Escherichia coli, with >95%, 0.005 EU/µg endotoxin level, suitable for Mass Spec, SDS-PAGE.

View Alternative Names

HRAS1, NRAS, GTPase NRas, Transforming protein N-Ras

2 Images
Mass Spectrometry - Recombinant Human NRAS (mutated G12D) Protein (His tag) (AB318947)
  • Mass Spec

Supplier Data

Mass Spectrometry - Recombinant Human NRAS (mutated G12D) Protein (His tag) (AB318947)

Mass determination by ESI-TOF. Predicted MW is 22290 Da (+/- 10 Da by ESI-TOF). Observed MW is 22155.07 Da.

SDS-PAGE - Recombinant Human NRAS (mutated G12D) Protein (His tag) (AB318947)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant Human NRAS (mutated G12D) Protein (His tag) (AB318947)

SDS-PAGE analysis of ab318947 under reducing conditions for 2ug protein.

Key facts

Purity

>95% HPLC

Endotoxin level

0.005 EU/µg

Expression system

Escherichia coli

Tags

His tag N-Terminus

Applications

SDS-PAGE, Mass Spec

applications

Biologically active

No

Mass Spectrometry

LC-MS/MS

Accession

P01111

Animal free

Yes

Carrier free

No

Species

Human

Storage buffer

pH: 7 Constituents: 20% Glycerol (glycerin, glycerine), 1.4586% Sodium chloride, 0.2691% Sodium phosphate dibasic heptahydrate, 0.1629% Sodium Phosphate Monobasic, 0.0148% (R*,R*)-1,4-Dimercaptobutan-2,3-diol

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "Mass Spec": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Sequence info

[{"sequence":"TEYKLVVVGADGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNSKSFADINLYREQIKRVKDSDDVPMVLVGNKCDLPTRTVDTKQAHELAKSYGIPFIETSAKTRQGVEDAFYTLVREIRQYRMKKLNSSDDGTQGCMGLPC","proteinLength":"Full Length","predictedMolecularWeight":"22.29 kDa","actualMolecularWeight":"22.16 kDa","aminoAcidEnd":0,"aminoAcidStart":0,"nature":"Recombinant","expressionSystem":null,"accessionNumber":"P01111","tags":[{"tag":"His","terminus":"N-Terminus"}]}]

Properties and storage information

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-80°C
Appropriate long-term storage conditions
-80°C
False

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The NRAS protein also known as neuroblastoma RAS viral oncogene homolog has a molecular weight of approximately 24 kDa. It functions mechanically as a GTPase cycling between an inactive GDP-bound state and an active GTP-bound state. The NRAS gene which encodes this protein shows expression in various tissues including the thymus leukocytes and other cells of the hematopoietic lineage. Activation of RAS involves the conversion to the GTP-bound form which enables NRAS to transmit signals within cells.
Biological function summary

NRAS plays an important role in cell proliferation differentiation and survival. It does not function alone but is part of the larger RAS protein family including HRAS and KRAS with whom it shares similar roles and sequence homology. NRAS interacts with various growth factor receptors and mediates signals to downstream effectors that influence cellular processes. Mutations in the NRAS gene can affect these biological processes leading to altered cell behavior.

Pathways

NRAS has significant roles in the MAPK/ERK pathway and the PI3K/AKT pathway. These pathways regulate fundamental cellular functions including growth and survival. NRAS interacts closely with other proteins such as RAF kinases and PI3K to propagate signals from activated receptors at the cell membrane to the nucleus. Altered NRAS activity can impact these pathways affecting cellular responses to external stimuli.

NRAS mutations are linked to certain cancers including melanoma and acute myeloid leukemia (AML). Mutant forms of NRAS result in constitutively activated RAS contributing to uncontrolled cell growth and survival. In melanoma NRAS mutations frequently co-occur with alterations in other proteins such as BRAF another member of the RAS/RAF/MEK/ERK pathway. Understanding NRAS's involvement in these conditions is critical for developing targeted therapeutic strategies.

Specifications

Form

Liquid

General info

Function

Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.

Sequence similarities

Belongs to the small GTPase superfamily. Ras family.

Post-translational modifications

Palmitoylated by the ZDHHC9-GOLGA7 complex (PubMed:16000296). Depalmitoylated by ABHD17A, ABHD17B and ABHD17C (PubMed:26701913). A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi (PubMed:15705808, PubMed:16000296, PubMed:2661017, PubMed:26701913).. Acetylation at Lys-104 prevents interaction with guanine nucleotide exchange factors (GEFs).. Fatty-acylated at Lys-169 and/or Lys-170.. Ubiquitinated by the BCR(LZTR1) E3 ubiquitin ligase complex at Lys-170 in a non-degradative manner, leading to inhibit Ras signaling by decreasing Ras association with membranes.. Phosphorylation at Ser-89 enhances NRAS association with its downstream effectors.. (Microbial infection) Glucosylated at Thr-35 by P.sordellii toxin TcsL.

Product protocols

Target data

Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
See full target information NRAS mutated G12D

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com